Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
08 2020
Historique:
received: 13 04 2020
accepted: 22 06 2020
revised: 13 08 2020
pubmed: 4 8 2020
medline: 8 10 2020
entrez: 4 8 2020
Statut: epublish

Résumé

Human cytomegalovirus (HCMV) is one of the main causative agents of congenital viral infection in neonates. HCMV infection also causes serious morbidity and mortality among organ transplant patients. Glycoprotein B (gB) is a major target for HCMV neutralizing antibodies, yet the underlying neutralization mechanisms remain largely unknown. Here we report that 3-25, a gB-specific monoclonal antibody previously isolated from a healthy HCMV-positive donor, efficiently neutralized 14 HCMV strains in both ARPE-19 cells and MRC-5 cells. The core epitope of 3-25 was mapped to a highly conserved linear epitope on antigenic domain 2 (AD-2) of gB. A 1.8 Å crystal structure of 3-25 Fab in complex with the peptide epitope revealed the molecular determinants of 3-25 binding to gB at atomic resolution. Negative-staining electron microscopy (EM) 3D reconstruction of 3-25 Fab in complex with de-glycosylated postfusion gB showed that 3-25 Fab fully occupied the gB trimer at the N-terminus with flexible binding angles. Functionally, 3-25 efficiently inhibited HCMV infection at a post-attachment step by interfering with viral membrane fusion, and restricted post-infection viral spreading in ARPE-19 cells. Interestingly, bivalency was required for HCMV neutralization by AD-2 specific antibody 3-25 but not the AD-4 specific antibody LJP538. In contrast, bivalency was not required for HCMV binding by both antibodies. Taken together, our results reveal the structural basis of gB recognition by 3-25 and demonstrate that inhibition of viral membrane fusion and a requirement of bivalency may be common for gB AD-2 specific neutralizing antibody.

Identifiants

pubmed: 32745149
doi: 10.1371/journal.ppat.1008736
pii: PPATHOGENS-D-20-00749
pmc: PMC7425986
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Epitopes 0
Viral Envelope Proteins 0
glycoprotein B, Simplexvirus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008736

Déclaration de conflit d'intérêts

I have read the journal's policy and the authors of this manuscript have the following competing interest: Tong-Ming Fu and Zhiqiang An filed a patent on 3-25 antibody.

Références

PLoS Pathog. 2015 Oct 20;11(10):e1005227
pubmed: 26484870
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2598-607
pubmed: 10509655
J Virol. 2017 Jul 12;91(15):
pubmed: 28490582
J Virol. 1995 Feb;69(2):1071-8
pubmed: 7815485
Antimicrob Agents Chemother. 2015 Mar;59(3):1558-68
pubmed: 25534746
J Gen Virol. 2002 Aug;83(Pt 8):2001-2005
pubmed: 12124464
Nucleic Acids Res. 2012 Jan;40(Database issue):D593-8
pubmed: 22006842
J Virol. 2010 Jul;84(14):7114-23
pubmed: 20463081
Birth Defects Res. 2017 Mar 15;109(5):336-346
pubmed: 28398680
Nat Commun. 2015 Sep 14;6:8176
pubmed: 26365435
PLoS Pathog. 2019 Jul 29;15(7):e1007914
pubmed: 31356650
Virology. 1993 Apr;193(2):834-41
pubmed: 8384757
Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):7043-7052
pubmed: 30894498
Clinics (Sao Paulo). 2015 Jul;70(7):515-23
pubmed: 26222822
Elife. 2018 Mar 07;7:
pubmed: 29513216
J Virol. 2017 Mar 13;91(7):
pubmed: 28077654
Vaccine. 2016 Jan 12;34(3):313-9
pubmed: 26657184
Transpl Infect Dis. 2011 Jun;13(3):318-23
pubmed: 20804536
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278
pubmed: 29686064
MAbs. 2014 Jul-Aug;6(4):879-93
pubmed: 24927271
Virology. 2013 Jan 20;435(2):239-49
pubmed: 23089254
J Infect Dis. 2018 May 25;217(12):1907-1917
pubmed: 29528415
J Intraven Nurs. 1999 Nov-Dec;22(6):331-5
pubmed: 10865601
J Virol. 2009 Apr;83(8):3891-903
pubmed: 19193805
Nature. 2008 Sep 18;455(7211):391-5
pubmed: 18701889
Mt Sinai J Med. 1999 Mar;66(2):113-24
pubmed: 10100416
Nat Microbiol. 2016 Jun 06;1(8):16082
pubmed: 27573107
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Immunochemistry. 1977 Mar;14(3):197-200
pubmed: 863464
PLoS Pathog. 2011 Aug;7(8):e1002172
pubmed: 21852946
J Virol. 2010 Jan;84(2):1005-13
pubmed: 19889756
J Gen Virol. 2003 Jul;84(Pt 7):1859-1862
pubmed: 12810880
PLoS Pathog. 2019 Jun 6;15(6):e1007716
pubmed: 31170257
PLoS Pathog. 2014 Oct 09;10(10):e1004377
pubmed: 25299639
Cell. 2018 Aug 23;174(5):1158-1171.e19
pubmed: 30057110
J Infect Dis. 1997 Mar;175(3):533-44
pubmed: 9041323
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
J Virol. 2010 Apr;84(8):3825-34
pubmed: 20130048
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
pubmed: 12393927
Oncotarget. 2017 Jun 3;8(43):73654-73669
pubmed: 29088734
Genome Announc. 2017 Jan 19;5(3):
pubmed: 28104650
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81
pubmed: 21460445
J Virol. 2015 Sep;89(17):8999-9009
pubmed: 26085146
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
pubmed: 16319222
PLoS Pathog. 2016 Mar 03;12(3):e1005454
pubmed: 26938634
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
NPJ Vaccines. 2017 Dec 14;2:36
pubmed: 29263890
Transfus Med Hemother. 2010;37(6):365-375
pubmed: 21483467
Nature. 2003 Jul 24;424(6947):456-61
pubmed: 12879076
mBio. 2013 Jun 04;4(3):e00332-13
pubmed: 23736286
Int J Mol Sci. 2018 Dec 11;19(12):
pubmed: 30544903
Science. 2017 Jun 30;356(6345):
pubmed: 28663444
Elife. 2013 Sep 10;2:e01456
pubmed: 24040512
Vaccine. 2014 May 7;32(22):2525-33
pubmed: 24681264
PLoS Pathog. 2014 Apr 17;10(4):e1004072
pubmed: 24743696
N Engl J Med. 2009 Mar 19;360(12):1191-9
pubmed: 19297572
Lancet. 2011 Apr 9;377(9773):1256-63
pubmed: 21481708
J Infect Dis. 2016 Dec 15;214(12):1916-1923
pubmed: 27923951
Antimicrob Agents Chemother. 2016 Jul 22;60(8):4961-71
pubmed: 27270290
Hum Vaccin Immunother. 2016 Aug 2;12(8):2106-2112
pubmed: 26986197
J Gen Virol. 1992 Sep;73 ( Pt 9):2375-83
pubmed: 1383409
Clin Microbiol Rev. 2013 Jan;26(1):86-102
pubmed: 23297260
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4997-5005
pubmed: 24297878
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7385-90
pubmed: 19372381
Vaccine. 2011 Oct 26;29(46):8350-6
pubmed: 21888937
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6267-6272
pubmed: 29712861
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
J Virol. 2007 Apr;81(8):3827-41
pubmed: 17267495
Clin Diagn Lab Immunol. 1997 Jan;4(1):107-11
pubmed: 9008292

Auteurs

Xiaohua Ye (X)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Hang Su (H)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.

Daniel Wrapp (D)

Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, United States of America.

Daniel C Freed (DC)

Merck Research Laboratory, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Fengsheng Li (F)

Merck Research Laboratory, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Zihao Yuan (Z)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Aimin Tang (A)

Merck Research Laboratory, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Leike Li (L)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Zhiqiang Ku (Z)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Wei Xiong (W)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Dabbu Jaijyan (D)

Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.

Hua Zhu (H)

Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.

Dai Wang (D)

Merck Research Laboratory, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Jason S McLellan (JS)

Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, United States of America.

Ningyan Zhang (N)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Tong-Ming Fu (TM)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.
Merck Research Laboratory, Merck & Co., Inc., Kenilworth, New Jersey, United States of America.

Zhiqiang An (Z)

Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH